Datapoint: Regence Sees 95% Biosimilar Adoption

Regence, the parent company of four Blues affiliates in Idaho, Oregon, Utah and Washington, last week said it has reduced specialty drug spend by $37 million after transitioning to the use of biosimilars. The company said it currently has a 95% adoption rate of biosimilars among its health plan members, and it expects costs to further decrease as more biosimilars become available in 2023. Regence’s four MCOs currently enroll 2,012,243 people in primary medical coverage, with 39.0% enrolled in risk-based commercial plans, and 54.4% in non-risk ASO plans.

Source: AIS’s Directory of Health Plans

0

0

0 Comments

0

0

• Datapoint